The RSI Indicator for ARTV moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In 10 of the 10 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 27 cases where ARTV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ARTV just turned positive on October 19, 2026. Looking at past instances where ARTV's MACD turned positive, the stock continued to rise in 17 of 20 cases over the following month. The odds of a continued upward trend are 85%.
Following a +12.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTV advanced for three days, in 95 of 108 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
ARTV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARTV entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.872) is normal, around the industry mean (2.973). P/E Ratio (-1.920) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (81.301) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ARTV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for SABS turned positive on October 21, 2026. Looking at past instances where SABS's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SABS's RSI Indicator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on SABS as a result. In 74 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +13.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in 168 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SABS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SABS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SABS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.288) is normal, around the industry mean (2.973). P/E Ratio (2.432) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SABS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| ARTV | SABS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | N/A | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 88% | 3 days ago 79% |
| Declines ODDS (%) | 1 day ago 85% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARTV’s FA Score shows that 1 FA rating(s) are green while SABS’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARTV’s TA Score shows that 5 TA indicator(s) are bullish while SABS’s TA Score has 5 bullish TA indicator(s).
ARTV (@Biotechnology) experienced а +9.81% price change this week, while SABS (@Biotechnology) price change was +13.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
ARTV is expected to report earnings on Nov 11, 2026.
SABS is expected to report earnings on Nov 13, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ARTV has been loosely correlated with RANI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTV jumps, then RANI could also see price increases.
| Ticker / NAME | Correlation To ARTV | 1D Price Change % | ||
|---|---|---|---|---|
| ARTV | 100% | -4.47% | ||
| RANI - ARTV | 47% Loosely correlated | -2.88% | ||
| RADX - ARTV | 44% Loosely correlated | -6.11% | ||
| SABS - ARTV | 34% Loosely correlated | +7.80% | ||
| CELC - ARTV | 34% Loosely correlated | +6.51% | ||
| AURA - ARTV | 32% Poorly correlated | N/A | ||
More | ||||
A.I.dvisor indicates that over the last year, SABS has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then REVB could also see price increases.
| Ticker / NAME | Correlation To SABS | 1D Price Change % | ||
|---|---|---|---|---|
| SABS | 100% | +7.80% | ||
| REVB - SABS | 48% Loosely correlated | +1.38% | ||
| INKT - SABS | 47% Loosely correlated | -5.27% | ||
| CYPH - SABS | 46% Loosely correlated | -10.51% | ||
| VYGR - SABS | 38% Loosely correlated | -7.92% | ||
| WHWK - SABS | 36% Loosely correlated | -1.07% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PMIO | 49.88 | 0.41 | +0.82% |
| PGIM Municipal Income Opportunities ETF (PMIO) | |||
| CLOB | 50.33 | 0.01 | +0.01% |
| VanEck AA-BB CLO ETF (CLOB) | |||
| ABLD | 31.25 | -0.41 | -1.30% |
| Abacus FCF Real Assets Leaders ETF (ABLD) | |||
| FLBR | 26.30 | -0.39 | -1.46% |
| Franklin FTSE Brazil ETF (FLBR) | |||
| MGC | 280.68 | -4.21 | -1.48% |
| Vanguard Morningstar Mega Cap ETF (MGC) | |||